Krystal Biotech Chief Commercial Officer Andrew Orth resigns

Krystal Biotech, Inc.

Andrew Orth resigned as Chief Commercial Officer, effective August 2, 2023.
No successor has been announced; reason for departure not disclosed.
The resignation is reported under Item 5.02 of Form 8-K.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Orth

Chief Commercial Officer

KRYS · Krystal Biotech, Inc.

Effective: 2023-08-02
Filed: August 7, 2023, 7:59 PM ET

Andrew Orth, the Company’s Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Orth resigned as Chief Commercial Officer at Krystal Biotech, Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

Andrew Orth, the Company’s Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.

View on SEC.gov

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.